AnneLAngiolilloMD

Pediatric Hematology & Oncology • Washington, DC

Professor, Pediatrics, G Washington University School of Medicine & Hlth Sci

Join to view full profile

Are you Dr. Angiolillo?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 58 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
111 Michigan Ave Nw
Washington, DC 20010
Phone+1 202-884-2140

Summary

Dr. Anne Angiolillo, MD is a pediatric hematologist/oncologist in Washington, District of Columbia. She is currently licensed to practice medicine in District of Columbia, Maryland, and Virginia. She is a Professor at G Washington University School of Medicine & Hlth Sci.

Education & Training

Children's National Hospital/George Washington UniversityFellowship, Pediatric Hematology/Oncology, 1992 - 1995
Children's National HospitalResidency, Pediatrics, 1989 - 1992
New York Medical CollegeClass of 1989

Certifications & Licensure

DC State Medical License 1991 - 2022
MD State Medical License 1995 - 2022
VA State Medical License 1995 - 2022
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Top Doctors:Washington DC Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Start of enrollment: 2001 Apr 01
Completed
Phase 2
Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia Start of enrollment: 2004 Jul 01
Completed
Phase 2
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Start of enrollment: 2008 Jul 21
Completed
Phase 3
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Completed
Phase 1
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Start of enrollment: 2019 Dec 27
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

549 citations
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.
Anne L. Angiolillo, Cecilia Sgadari, D D Taub, Fang Liao, J M Farber
The Journal of Experimental Medicine. 1995-07-01
75 citations
Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Re...
Anne L. Angiolillo, Reuven J. Schore, Meenakshi Devidas, Michael J. Borowitz, Andrew J. Carroll
Journal of Clinical Oncology. 2014-12-01
133 citations
The genomic landscape of pediatric acute lymphoblastic leukemia.
Samuel W Brady, Kathryn G Roberts, Zhaohui Gu, Lei Shi, Stanley Pounds
Nature Genetics. 2022-09-01